Psoriasis is a chronic systemic immune-mediated inflammatory dermatosis associated with several comorbidities. Psoriasis patients are at increased risk of developing cardiovascular diseases (CVD), namely, coronary heart disease, stroke or peripheral vascular disease, and psoriasis seems to be an independent cardiovascular risk factor. Antipsoriatic systemic therapy, especially anti-tumor necrosis factor (TNF)-a, seems to exert a beneficial effect on these comorbidities. The purpose of this study was: (i) to measure the level of cardiovascular serum markers in psoriasis patients in comparison with healthy volunteers; and (ii) to compare the serum level of the same markers in patients before and 3 months after adalimumab therapy. We investigated six biomarkers connected to CVD: Creactive protein (measured high sensitively, hsCRP), oxidized low-density lipoproteins (oxLDL), oxLDL/b-glycoprotein I complex (oxLDL/b2GPI), vascular endothelial adhesion molecule 1 (VCAM-1), E-selectin and interleukin (IL)-22. These biomarkers were measured in 21 patients with moderate/severe psoriasis before and after treatment with adalimumab and in healthy volunteers. hsCRP (P < 0.05), oxLDL-b2GPI complex (P < 0.05), E-selectin (P < 0.001) and IL-22 (P < 0.001) were significantly increased in comparison with healthy controls, whereas oxLDL and VCAM-1 were also higher in psoriasis patients but the difference did not reach statistical significance. A decrease of E-selectin (P < 0.001) and IL-22 (P < 0.001) was observed after 3 months of adalimumab therapy. Inhibition of TNF-a seems to not only improve psoriasis but also decreases serum cardiovascular biomarkers. E-selectin and IL-22 could serve for monitoring of the efficacy of antipsoriatic systemic therapy on cardiovascular risk.
INTRODUCTION
Psoriasis is a chronic systemic immune-mediated inflammatory skin disease, which is associated with various comorbidities. Its prevalence in the world population is 2-4%. 1 For decades, psoriatic arthritis was considered the main associated disease, which can be present in up to 20% of patients with psoriasis. 1 Recently, new information has arisen concerning other concomitant diseases like obesity, hyperglycemia, dyslipidemia, arterial hypertension (all components of metabolic syndrome), inflammatory bowel disease and depression. Patients with psoriasis are at increased risk of developing cardiovascular disease (CVD), namely, coronary heart disease, stroke or peripheral vascular disease, and it seems that psoriasis becomes an independent cardiovascular risk factor. [2] [3] [4] [5] [6] [7] It is assumed that systemic inflammation associated with psoriasis may trigger different inflammatory events, which lead to insulin resistance and eventually atherosclerosis. This has been described as the "psoriatic march". 8 Different authors observed higher common carotid artery intima-media thickness (IMT) in patients with severe psoriasis compared with control subjects, 9 while others measured various cardiovascular biomarkers. 10, 11 Interestingly, even in patients with mild psoriasis subclinical systemic and vascular inflammation detected by 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET)/computed tomography (CT) has been described. 12 Systemic therapy for psoriasis, for example, methotrexate or tumor necrosis factor-a inhibitors (anti-TNF-a), seems to be an effective approach to decrease cardiovascular events in psoriasis patients. 13 Pina et al.
14
showed that adalimumab therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis, while Jok ai et al. 15 in a pilot study showed decrease of IMT after treatment with adalimumab, infliximab and etanercept. Similarly, in a rheumatological study, significant reduction in aortic inflammation was seen after 8 weeks of anti-TNF-a therapy by using FDG-PET with CT coregistration. 16 In our study, the following biomarkers implicated in CVD were measured in patients with moderate/severe psoriasis before and after treatment with adalimumab as well as in healthy controls: C-reactive protein (measured by highly sensitive assay, hsCRP) as a general marker of inflammation; oxidized low-density lipoprotein (oxLDL) indicating oxidative modification of the most atherogenic lipoprotein LDL; oxLDL/bglycoprotein I complex (oxLDL/b2GPI) which forms complexes with plasma immunoglobulins (Ig) and has been co-localized with immunoreactive lymphocytes in atherosclerotic lesions; [17] [18] [19] markers of endothelial dysfunction vascular endothelial adhesion molecule 1 (VCAM-1) and E-selectin; and interleukin (IL)-22 which is an effector cytokine of CD4 + T-helper (Th)22 and its increased concentrations was observed in patients with manifest atherosclerosis. 20, 21 We hypothesized that psoriasis patients would show higher plasma concentrations of investigated biomarkers compared with age-, sex-and body mass index (BMI)-matched healthy control individuals and that anti-TNF-a therapy (adalimumab) would reduce their plasma levels and consequently the risk of CVD.
METHODS
A total of 21 (12 female and nine male) patients with plaque type psoriasis and a Psoriasis Area and Severity Index (PASI) of more than 10, who were naive to biologic therapy and had received no systemic therapy in the last 3 months, were included in the study. Patients with psoriatic arthritis were excluded, and also patients with hypercholesterolemia, hypertriglyceridemia, diabetes mellitus and hypertension to lower the risk of bias. Venous blood was obtained before and 3 months after therapy with adalimumab on the classic dose regimen for psoriasis (80 mg s.c. injection on the baseline followed by 40 mg after a week and then 40 mg every other week). Similarly, 21 healthy volunteers were recruited to obtain age-, sexand BMI-matched groups. The study was approved by the local ethics committee and all investigated subjects gave informed consent prior to their participation. For sample preparation, 10 mL of venous blood was collected in serum tubes in the morning, after a minimum of 10 h fasting, and allowed to clot. Subsequently, the tubes were centrifuged at 2000 g for 10 min at room temperature and the serum samples were stored at À70°C until further analysis.
All selected markers were estimated by high-sensitivity enzyme-linked immunoassay (ELISA)-based assay using: an oxLDL ELISA kit (Mercodia, Uppsala, Sweden), oxLDL/B2GPI antigen complex ELISA kit (Corgenix, Broomfield, CO, USA), VCAM-1 ELISA kit (eBioscience, Bender MedSystems, Vienna, Austria), E-selectin ELISA kit (R&D Systems, Minneapolis, MN, USA), CRP ultrasensitive ELISA kit (BioVendor, Brno, Czech Republic) and IL-22 ELISA kit (R&D Systems).
We used a single sample from patients and healthy subjects. Statistical analysis was performed by using Statistica 8.0 software (Statsoft, Tulsa, OK, USA). For comparison of two independent samples with normal distribution Student's t-test was used, and analysis of multiple groups was performed by using the ANOVA test. Correlation analyses were performed using the Pearson correlation coefficient. P < 0.05 was considered statistically significant.
RESULTS

Biomarkers of psoriasis patients versus control subjects
At baseline, the patients with moderate/severe psoriasis had significantly higher serum concentrations of hsCRP (3. 
Correlation analyses
There was no correlation of the PASI score with any of the investigated markers in psoriasis patients. The mean value of PASI score was 27. The psoriasis and control groups were well matched for age, sex and BMI (Table 1) . BMI showed no correlation with studied markers compared with healthy control subjects.
Levels of biomarkers after adalimumab therapy
After 3 months on adalimumab therapy, a significant reduction of the PASI score was achieved (P < 0.001); the mean level dropped from 27 to 1.1 ( Figure 2) Figure 3 .
DISCUSSION
The evidence of an increased cardiovascular risk in patients with psoriasis has been getting stronger in the last few years. The association between obesity and elevated pro-inflammatory cytokines and adipokines has been well documented. Insulin resistance contributes to endothelial dysfunction which predisposes patients to risk of atherosclerosis. 22 Furthermore, different cardiovascular biomarkers, which have been investigated in psoriasis, share many features with atherosclerosis, supporting the hypothesis of an increased CVD risk in these patients. 11, 23 Pina et al. have described asymmetric dimethylarginine (ADMA) and osteoprotegerin (OPG), two biomarkers associated with CVD in 29 patients with moderate to severe Figure 1 . Serum concentrations of highly sensitive C-reactive protein (hsCRP), oxidized low-density lipoproteins (oxLDL), oxidized low-density lipoprotein/b-glycoprotein I complex (oxLDL-b2GPI), vascular endothelial adhesion molecule 1 (VCAM-1), E-selectin and interleukin (IL)-22 in 21 psoriasis patients and 21 healthy controls. hsCRP (P < 0.05), oxLDL-b2GPI complex (P < 0.05), E-selectin (P < 0.001) and IL-22 (P < 0.001) were statistically significantly increased in comparison with healthy controls, whereas oxLDL and VCAM-1 were also higher in psoriasis patients but the difference did not reach statistical significance. SD, standard deviation; SEM, standard error of the mean.
psoriasis, and they found that that ADMA correlates with the severity of psoriasis. 24 In another study, the authors investigated the correlation of leptin and resistin with metabolic syndrome features and disease severity in psoriasis patients. They showed that leptin correlates with metabolic syndrome and inflammation, whereas resistin correlates with inflammation and disease severity. 25 Newly, trabecular bone score (TBS), a method developed to be used to indirectly evaluate bone microarchitecture, therefore providing skeletal data not captured from the standard dual-energy X-ray absorptiometry, has been investigated in psoriasis patients for this association with inflammation and adiposity. The authors found no correlation between TBS and disease severity but TBS was negatively associated with weight, BMI, waist perimeter, fat percentage and systolic and diastolic blood pressure, and the conclusion was that TBS correlates with metabolic syndrome features and inflammation in patients with psoriasis. 26 The hypothesis that anti-TNF-a therapy can have a beneficial effect in the risk of atherosclerosis is getting stronger. In a cohort of 29 patients treated for 6 months with adalimumab therapy, a statistically significant improvement (P = 0.008) of insulin sensitivity was observed after adalimumab treatment. 27 The same authors showed that anti-TNF-a therapy achieved statistically significant reduction (P = 0.0001) of retinol-binding protein 4 (RBP4) serum levels. RBP4 is an adipokine considered to be highly linked with subclinical atherosclerosis due to its positive correlation with carotid intima-media thickness. Serum levels of retinol binding protein 4 have not only been found to be increased in patients with moderate to severe psoriasis but they also correlate with disease activity. 28 Our study was focused on six biomarkers associated with atherosclerosis in patients with moderate/severe psoriasis. At first, we compared the plasma concentrations of these markers to control healthy individuals and then measured their levels after 12 weeks of adalimumab therapy. We decided on the 3-month interval because, according to the local regulations, after 3 months on therapy we have to decide if we will continue on the same biologic therapy or switch to another due to ineffectiveness. Additionally, the same time periods of the therapy for control of biomarkers was used by other authors. Sigurdardottir et al. 29 measured six cardiovascular risk markers in 28 patients before and 12 weeks after therapy with etanercept. Further analysis using a longer interval on adalimumab therapy is planned in our patient cohort. We focused on inflammatory markers being indicative of cardiovascular risk. IL-22 belongs to the IL-10 family cytokine and has been quite recently discovered to be produced by Th17 and mainly Th22 cells. IL-22 acts primarily on tissue cells such as epithelial and smooth muscle cells. It can activate various signaling pathways including the Janus kinase/signal transducers and activators of transcription (JAK/STAT). Its pathogenesis in psoriasis has been explored and it has been found that IL-22 can inhibit keratinocyte terminal differentiation and can induce psoriasis-like epidermis alterations. Lately, the role of IL-22 in the development of atherosclerosis has been described as it has been shown to be present in atherosclerotic plaques. 20 Interestingly, Wang et al. 30 described that IL-22 showed metabolic benefits after administration of exogenous IL-22 in genetically obese leptin receptor-deficient (db/db) mice and mice fed with a high-fat diet by improving hyperglycemia and insulin resistance. This needs further investigation because available biologic therapy for psoriasis which blocks IL12/23 (ustekinumab) and subsequently IL-22 has not shown a negative effect on metabolic syndrome. 31 In our psoriasis patients, IL-22 was not only significantly higher than in the control group but also showed an impressive decrease after the adalimumab therapy. The adhesion molecules measured in our study were VCAM-1 and E-selectin which are generally considered markers of endothelial activation and dysfunction and are associated with an increased risk of atherosclerosis and manifestation of cardiovascular disease. In human studies, . Serum concentrations of highly sensitive C-reactive protein (hsCRP), oxidized low-density lipoproteins (oxLDL), oxidized low-density lipoprotein/b-glycoprotein I complex (oxLDL/b2GPI), vascular endothelial adhesion molecule 1 (VCAM-1), E-selectin and interleukin (IL)-22 in the plasma of patients with psoriasis before and after 12 weeks of adalimumab therapy. On the graph we can observe a significant decrease of E-selectin (P < 0.001) and IL-22 (P < 0.001) after treatment. SD, standard deviation; SEM, standard error of the mean.
increased concentrations of circulating soluble adhesion molecules have been reported in patients with systemic inflammatory and cardiovascular diseases. 32, 33 VCAM-1 has not only be detected in psoriatic lesions but also in dermal vessels and is supposed to be expressed by Langerhans cells and T lymphocytes of the dermal inflammatory infiltrate. E-selectin is a proinflammatory soluble cell-adhesion molecule which plays a significant role in the development of atherosclerosis by recruiting circulating leukocytes to the vascular endothelium enhanced by TNF-a and CRP [34] [35] [36] E-selectin was not only statistically increased in psoriasis patients in comparison with healthy volunteers, which is consistent with results from other authors, 36 but showed a significant decrease after anti-TNF therapy. E-selectin maybe elevated in various conditions like infections, vasculitis or systemic inflammation such as psoriasis. The decrease after adalimumab therapy probably primarily reflects the improvement of psoriasis but secondarily contributes in lowering the cardiovascular risk by decreasing the serum level of E-selectin, an adhesion molecule involved in atherosclerosis. VCAM-1 was also higher compared with controls and showed a decrease after therapy, but the values did not show statistical differences. Oxidized low-density lipoprotein causes activation of endothelial cells through the lectin-like oxidized low-density lipoprotein receptor-1 which is one of the factors leading to atherosclerosis because oxidized LDL may be primarily cytotoxic to endothelial cells. 37 Ren et al. 38 showed that oxLDL causes injury to endothelial cells via activation of different signal transduction pathways such as those involving protein kinase C and mitogen-activated protein kinase. In the arterial intima, oxidized LDL are readily absorbed by macrophages via the scavenger receptors, resulting in their transformation into foam cells. These play a crucial role in the atherosclerotic plaque initiation and progression. Accumulation of oxLDL in psoriatic skin has been also described. 39 The oxLDL/b2GPI complex, a parameter of both oxidative stress and inflammation, induces autoantibody production (both IgG and IgM) 40 and further becomes a pro-inflammatory chemotactic factor for macrophages and T lymphocytes within the atherosclerotic lesion. 41 In our study, the mean concentrations of both oxLDL and oxLDL/b2GPI were higher in psoriasis patients than in controls, though the difference in oxLDL did not reach statistical significance. Similar results were found by other authors where they also were not able to show differences in OxLDL serum levels between psoriasis patients and control groups, 10 but more studies on larger cohorts of patients are needed to conclude if OxLDL can be a sensitive cardiovascular marker for psoriasis patients. In contrast, oxLDL/b2GPI might be a better marker of cardiovascular risk in psoriasis patients than oxLDL, and to our knowledge this is the first time that this marker has been investigated in relation to psoriasis. After 12 weeks of adalimumab therapy, both oxLDL and oxLDL-b2GPI slightly increased, though not significantly. It is well known that some patients on anti-TNF-a therapy gain weight after initiation of treatment and this fact may be associated with increased liver synthesis of very low-density lipoproteins which partly convert to LDL. Detailed lipoprotein analysis was not performed in this study, however. A further limitation was a relatively low number of investigated patients and measuring of the biomarkers after 12 weeks only. As a marker of systemic inflammation, hsCRP is believed to predict cardiovascular events, for example, acute myocardial infarction or ischemic cerebrovascular stroke. 42, 43 In this study, hsCRP was higher in psoriasis patients compared with healthy controls. After adalimumab therapy, serum levels of hsCRP were decreased; however, they did not achieve statistically significant results. We did not observe any correlation of the PASI score with any of the investigated markers in psoriasis patients. Similar results were demonstrated by Sigurdardottir et al. 29 suggesting that the elevation of the markers is connected with systemic inflammation rather than psoriasis activity.
In conclusion, patients with psoriasis showed higher plasma concentrations of different biomarkers associated with atherosclerosis (hsCRP, oxLDL/b2GPI, E-selectin and IL-22) when compared with healthy volunteer subjects. In particular, the oxLDL/b2GPI complex as a new marker of atherosclerosis in psoriasis patients seems to be promising. After 12-week therapy with adalimumab, the levels of E-selectin and IL-22 as well as the PASI score dropped significantly. Thus, the anti-TNF-a administration may not only alleviate clinical symptoms but also contribute to lowering cardiovascular risk in patients with psoriasis vulgaris. A limitation of this pilot study is the low number of enrolled patients and the short follow up after
